London, UK — Dividend stocks offer a great way to grow your money over time. Moreover, these equities tend not to be as volatile compared with their pure-play growth counterparts–a feature that should appeal to individuals concerned about the current state of our U.S markets.
The key here is finding companies that pay dividends so you can benefit fully from market growth without worrying too much if there’s an economic downturn or not!
Jane Tyler, a broker at HubbleBit, says that investors should have Amgen and National Research Corporation on their radars. Jane specifically likes these two stocks because they offer high dividends with low volatility levels–a perfect recipe for success in this market!
A safe haven that has been shown to be effective
Investors have been bidding up Amgen by a healthy 7.5% this year, even though it’s going through an uneven period from a top-line growth standpoint.
A blue-blooded biotech company called “Amgen” which many people are familiar with because they make drugs for human ailments such as cancer and arthritis, among others, was riding high on its success until around 2003, when things started getting worse rather than better despite having spent big money trying out new therapies that would help them get back into the game but all those efforts seemed quaint now compared to what came next.
National Research Corporation, Jane Tyler’s other top pick, is a little less well-known but has a long history of success as a dividend payer. This company has been in business since 1946 and currently pays an annual dividend yield of 3.8%
Both Amgen and National Research Corporation have low volatility levels and high dividend yields, making them perfect picks for individuals looking to protect their portfolios while also generating income. Investors who purchase these stocks should see healthy returns in the coming years!
Investors have been rushing to this leading biopharmaceutical company in recent weeks for two primary reasons:
- Amgen’s payout ratio is a great indication that its quarterly distribution will be safe. The company has an above-average yield and low historical volatility, making it worth investing in even during rough market periods like these!
- The biotech Amgen is expected to see its top line perk up as early as next year, thanks in part to Lumakras, Tezspire and their biosimilar franchise. However, Wall Street estimates that annual sales will take a hit due to COVID-19 related issues, which have occurred recently, but they’re still projected for growth starting in 2020 with an increase of 4%.
Whether it’s the Dow Jones or NASDAQ100, Amgen is well-positioned to continue delivering market-beating gains for years. With their top-notch dividend program in place and a horizon that includes both lofty goals while remaining grounded at heart, they should be able to withstand any volatility this exceptionally volatile climate may bring upon us all.
A healthcare SaaS with a growing and recurring revenue stream.
The old rule of thumb is that you should invest in companies with high dividends because they’re safe, steady earnings. But what if I told you there was a way for investors to get more out of their money by investing in these types?
The National Research Corporation has found success through using this strategy and now wants others to follow suit!
The healthcare industry has seen immense growth over the years, but it still has some drawbacks. For example, there are very few companies out on this front who’ve been able to attract investment from big players like Wall Street banks or Fortune 500 firms because most people don’t see what they can offer, which makes them less likely candidates for merger talks down the line according to NRC Health – with an exception being when someone wants both parts acquired instead; something you’ll be able does if your shares come through nicely!
NRC Health’s software-as-a-service (SaaS) platform empowers healthcare organizations with data-driven solutions for a better understanding of what matters most to each individual they serve. By collecting and analyzing mountains of patient feedback, the company helps hospital systems have higher quality care by acquiring more loyal patients as well as retaining them longer than before through innovative insights into how people perceive their experience from start until the finish – all while making sure that you’re meeting every need along this journey.
With the USD 965 million healthcare company, you can have a more detailed conversation with your patient before their appointment. This way, they will know what to expect and be less anxious about it all!
The care team’s ability to personalize patient experience and outcomes will lead healthcare systems towards improved customer satisfaction, better clinical performance, and reduced overall expenses for both patients and providers.
In the most recent quarter, NRC Health achieved double-digit revenue and operating income growth with help from its subscription-based model. Plus, they’re gaining traction by cross-selling other products to clients who want more than just one solution for their care needs–up 17% in Q4 of this year alone! The number of people utilizing multiple solutions was also up slightly at 28%, but it’s important not to get too excited about these small fluctuations because we don’t know if or when there will be another rise yet again…but you can bet that trend won.
When patients are happy with their care, it’s likely that they will stay healthy and reduce the risk of them filing lawsuits against hospitals or doctors. This means a better payment from Medicare/ Medicaid for services provided!
The most interesting thing about NRC Health is that it has a unique blend of safety and growth. With revenue growing 10% year-over, there’s no sign yet for hospitals to start cutting back on customer satisfaction in order just to get their profits up even higher than before–they’re still incentivized by those tailwinds, after all! And when you add 2%.4%, it’s not hard whatsoever to see why this healthcare stock might be more tempting than ever before…
Disclaimer: Our content is intended to be used for informational purposes only. It is very important to do your own research before making any investment based on your own personal circumstances. You should take independent financial advice from a professional in connection with, or independently research and verify, any information that you find on this article and wish to rely upon, whether for the purpose of making an investment decision or otherwise.